JPMorgan | China Healthcare: Recent Roadshow Takeaways — CXO Favored for 'Certainty,' Biotech Still Awaiting a 'Capital-Magnet' Theme
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
JPMorgan distills roughly 20 investor meetings held across mainland China from August 3 to 6. China healthcare fundamentals remain solid, with innovative-drug-related segments staying resilient in 2H26, but returns are being driven more by cross-sector fund rotation than by fundamentals. Anti-corruption and geopolitical risks are acknowledged, yet clients mostly treat them as background noise rather than core pricing concerns.
CXO is the highest-conviction trade, favored for earnings certainty and visibility, while innovative drug and biotech names — despite recognized innovation and active first-half BD activity — lack a single 'capital-magnet' theme in 2H26 capable of drawing large generalist inflows. Overseas investors still doubt whether Chinese clinical data can convert into global registrational outcomes, which compresses valuations, while AIDD draws heavy attention without mature underwriting or valuation frameworks. Offline pharmacies are held as defensive positions with improving same-store sales; elective medical services demand is unlikely to recover quickly.
JPMorgan prefers biotech and CXO: Kelun-Biotech (6990.HK, OW, HK$539.50), Innovent Biologics (1801.HK, OW, HK$94.85), surgical robotics maker MicroPort MedBot (2252.HK, OW, HK$23.22), WuXi AppTec A/H (603259.SS/2359.HK, OW, Rmb154.82/HK$192.30) and WuXi Bio (2269.HK, OW, HK$45.86). Sac-TMT's 2H26 global Phase 3 readout and FDA BLA acceptance are key potential unlocks.